Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants

References

• National Heart, Lung, and Blood Institute. What is atrial fibrillation? U.S. Department of Health and Human Services 2015. Available at: http://www.nhlbi.nih.gov/health/health-topics/topics/af. [Last accessed Q2 15 October 2015]
   Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015;131:e29-e322
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142-7
   PubMed Web of Science ®Google Scholar
• Wolf PA, Singer DE. Preventing stroke in atrial fibrillation. Am Fam Physician 1997;56:2242-50
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Stettin GD. Treatment of nonvalvular atrial fibrillation. West J Med 1995;162:331-9
   PubMedGoogle Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
   PubMed Web of Science ®Google Scholar
• Fitch K, Broulette J, Swong WJ. The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis. Am Health Drug Benefits 2014;7:200-9
   PubMedGoogle Scholar
• Mercaldi CJ, Siu K, Sander SD, et al. Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fibrillation. Cardiol Res Prac 2012;2012:645469. doi: 10.1155/2012/645469. Epub 2012 Oct 2
   PubMedGoogle Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:1144-50
   PubMed Web of Science ®Google Scholar
• Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel oral anticoagulants and reversal agents: considerations for clinical development. Am Heart J 2015;169:751-7
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2Suppl):e531S-575S
   Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:2246-80
   Web of Science ®Google Scholar
• Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 2014;30:1114-30
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016;50:e1-e88
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hess G. Dabigatran exteliate is associated with shorter hospital length of stay and lower hospital costs compared to warfarin in treatment-naïve, newly diagnosed non-valvular atrial fibrillation patients. Circulation: Cardiovascular and Quality and Outcomes. 2012;5:A282.
   Google Scholar
• Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 2012;15:776-85
   PubMedGoogle Scholar
• Francis K, Yu C, Alvrtsyan H, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin 2015;24:1-7
   Google Scholar
• Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemostasis 2012;108:476-84
   PubMed Web of Science ®Google Scholar
• Bancroft T, Lim J, Wang C, et al. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther 2016;38:545-556 e1-e6
   PubMed Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
   PubMed Web of Science ®Google Scholar
• Mucha L, Masia NA, Azelsen KJ. Per-patient-per-month drug costs in Medicare part D protected classes. Pharmacoeconomics 2006;24:79-84
   PubMed Web of Science ®Google Scholar
• Farr AM, Johnston SS, Ritchings C, et al. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting. J Med Econ 2016;19:386-96
   PubMed Web of Science ®Google Scholar
• Hao Y, Li N, Fang AP, et al. Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2– Metastatic breast cancer receiving everolimus-based therapy or chemotherapy. Adv Ther 2016;33:983-97
   PubMed Web of Science ®Google Scholar
• Palmer JB, Li Y, Herrera V, et al. Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord 2016;17:261. doi: 10.1186/s12891-016-1102-z
   PubMed Web of Science ®Google Scholar
• Vekeman F, Sasane M, Cheng WY, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thealassemia. J Med Econ 2016;19:292-303
   PubMed Web of Science ®Google Scholar
• Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm 2004;10:159-65
   PubMedGoogle Scholar
• Johnson BH, Smoyer-Tomic KE, Siu K, et al. Readmission among hospitalized patients with non-valvular atrial fibrillation. AJHP 2013;70:414-22
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173-80
   PubMed Web of Science ®Google Scholar
• van den Ham HA, Klungel OH, Singer DE, et al. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol 2015;66:1851-9
   PubMed Web of Science ®Google Scholar
• Roldan V, Marin F, Manzano-Fernandez S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2013;62:2199-204
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
   PubMed Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
   PubMed Web of Science ®Google Scholar
• Amin A, Stokes M, Makenbaeva D, et al. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. J Med Econ 2014;17:771-81
   PubMedGoogle Scholar
• Bengtson LGS, Lutsey PL, Chen LY, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol 2017;69:868-876. doi: 10.1016/j.jjcc.2016.08.010. Epub 2016 Nov 23.
   PubMed Web of Science ®Google Scholar
• Fu A, Jain R, Sander SD, et al. Healthcare resource utilization and costs among patients with non-valvular atrial fibrillation using dabigatran or warfarin for stroke prevention. Circulation: Cardiovascular Quality and Outcomes 2014;7:A242
   Google Scholar
• Sussman M, Ghate S, Sutherland SP, et al. Resource use among nonvalvular atrial fibrillation patients. Am J Pharm Benefits 2016;8:84-92
   Web of Science ®Google Scholar
• Amin A, Stokes M, Makenbaeva D, et al. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. J Med Econ 2014;17:771-81
   PubMedGoogle Scholar
• Laliberté F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther 2015;32:216-27
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Real-world evaluation of healthcare resource use and costs of elderly patients with nonvalvular atrial fibrillation treated with apixaban vs warfarin in the US. Circulation 2016;134:A17298
   Google Scholar
• Gilligan AM, Gandhi P, Song X, et al. Comparison of all-cause healthcare resource utilization and costs among patients with non-valvular atrial fibrillation, newly treated with dabigatran or warfarin. Am J Cardiovasc Drugs 2017. doi: 10.1007/s40256-017-0244-1. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Amin A, Jing Y, et al. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. J Med Econ 2013;16:1163-8
   PubMedGoogle Scholar
• Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 2016;116:975-986
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin 2017;33:1745-54
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016;176:1662-71
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin 2016;32:573-82
   PubMed Web of Science ®Google Scholar